The predicted deficit in manufacturing capacity for biologic drugs
that has been tipped to impede the development of the market has
not materialised, with capacity exceeding demand, according to new
Overcapacity remains the main issue affecting the European market
for active pharmaceutical ingredients, with lack of capability
differentiation and competition from low-cost manufacturers also
holding back growth in the sector.
Lonza has commissioned a new current Good Manufacturing
Practice-compliant facility for the production of microbially
derived biopharmaceuticals at its largest worldwide production
centre in Visp, Switzerland.
Drug maker Samaritan Pharmaceuticals, has entered into a
collaboration with Pharmaplaz to produce and supply Samiritan's
lead compound and pipeline of drugs that includes treatments for
AIDS, Alzheimer's, cancer and cardiovascular...
Unichem Laboratories of India, a major supplier of active
pharmaceutical ingredients (APIs) and finished pharmaceuticals in
the country, has entered into an alliance that could see it
supplying generics into the US market.
Rhodia Pharma Solutions' Chambers Works facility in New Jersey is
now up and running. The company supplies preclinical and clinical
trial materials and launch volumes of active pharmaceutical
ingredients (APIs) and intermediates...
Akzo Nobel has unveiled a plan to 'fix' its troubled
pharmaceuticals businesses, hit by patent expirations, safety
concerns with some core product lines and a difficult operating
environment for contract manufacturing of...